Biotech Values

[AlpineBV_Miller]

Dew -

I'm interested in hearing what Tx you think Roche missed in the P2 trial. Patients had to have failed Herceptin, Tarceva, an anthracycline, taxanes, and capecitabine. Of the 120 pts in the trial, all met these criteria save one person who did not have a taxane. The emdian number of therapies for M+ disease was 7, the median number of all BCa therapies was 8.

The FDA seemed to indicate that Roche missed some non-targeted therapy. I'd be interested to hear what you think that therapy(ies) might be.